Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
  • Submission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EU
  • Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that can drastically affect an individual’s everyday life and requires life-long treatment
  • Sandoz is committed to accelerating patient access to potentially life-changing, high-quality treatments, while generating savings for healthcare systems and patients

Basel, July 25, 2022 …

Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
  • Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study
  • Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic immune-mediated inflammatory diseases
  • Sandoz is committed to supporting healthcare professionals to advance patient care and improve access to medicines sustainably and affordably

Basel, July 21, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today …

Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance

Ad hoc announcement pursuant to Art. 53 LR

  • Q2 sales grew +5% cc1 (-1% USD)
    • Innovative Medicines (IM) sales grew +5% cc (-1% USD); strong performance of key growth brands including Entresto (+33% cc), Kesimpta (+270% cc), Cosentyx (+12% cc), Kisqali (+43% cc) and Zolgensma (+26% cc)
    • Sandoz sales grew +5% cc (-3% USD) benefiting from a return towards normal business dynamics, with growth across all business …